| Tufts Medicine

ASSESS (Alport Syndrome Sema3A Efficacy & Safety Study)

A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome.

Alport's syndrome

All genders

18-45

Division of Nephrology

Tufts Medical Center

Learn more

By admin, 2 March, 2026

Lisa Lavarnway-Comeau, MSN, APRN, FNP-C

By admin, 2 March, 2026

Suchita Kumar, MD

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer (ReDiscover-2)

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

Breast cancer, Locally advanced and metastatic breast cancer

All genders

18+

Recruiting now

Cancer Center

Tufts Medical Center

Learn more

By kbarbin, 2 March, 2026

National Nutrition Month® and Food Drive at Tufts Medical Center

Celebrate National Nutrition Month

Hosted by Frances Stern Nutrition Center

Join us in the Tufts Medical Center Atrium Lobby for National Nutrition Month®, hosted by the Frances Stern Nutrition Center, and help support our community through a food drive benefiting the Boston Rescue Mission.

By admin, 27 February, 2026

Kerrilyn Pessin, NP

By admin, 27 February, 2026

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians